{"id":154377,"date":"2026-11-17T17:33:03","date_gmt":"2026-11-17T08:33:03","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4884-20261117-01_wp_earnings_guidance\/"},"modified":"2026-11-17T17:33:03","modified_gmt":"2026-11-17T08:33:03","slug":"4884-20261117-01_wp_earnings_guidance","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/","title":{"rendered":"Q&#038;A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026"},"content":{"rendered":"<p>Published a summary of the Q&#038;A from the full-year financial results briefing for the fiscal year ended September 2026. Key discussion points included preparing the U.S. spinal cord injury development for a Ready-to-Go state, establishment of HGF active pharmaceutical ingredient (API) manufacturing, progress and data disclosure timing for the vocal fold scarring treatment Phase III, orphan designation progress, funding plan and approximately 2.2 billion yen use of proceeds, collaboration versus in-house development strategy, and strategic shareholders\u2019 investment purposes and potential for long-term holding.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4884","jir_company_name":"Kringle Pharma, Inc.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-17","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4884-20261117-01.pdf","jir_short_summary":"Published a summary of the Q&A from the full-year financial results briefing for the fiscal year ended September 2026. Key discussion points included preparing the U.S. spinal cord injury development for a Ready-to-Go state, establishment of HGF active pharmaceutical ingredient (API) manufacturing, progress and data disclosure timing for the vocal fold scarring treatment Phase III, orphan designation progress, funding plan and approximately 2.2 billion yen use of proceeds, collaboration versus in-house development strategy, and strategic shareholders\u2019 investment purposes and potential for long-term holding.","jir_summary":"### Business Development and R&D Investment Explanation\nThe company clarified its policy to advance preparations for the Phase III acute spinal cord injury trial in the U.S. to a Ready-to-Go state. It will carry out funding to accelerate trial initiation and explore non-dilutive funding and partnership-based financing options. The policy is to pursue clinical development and manufacturing in parallel, including building HGF API manufacturing capabilities, establishing U.S. manufacturing infrastructure, and preparing for the regulatory filing for the vocal fold scarring treatment.\n\n### Funding and Capital Policy\nThe plan targets fundraising on the order of 2.2 billion yen to promote preparation for the U.S. Phase III trial, construct HGF API manufacturing capabilities using a new manufacturing method, and cover domestic manufacturing costs and working capital. The exercise price structure is two-tiered, with 1,000 yen reflecting a market capitalization exceeding 10 billion yen and aligning with IPO offering price considerations. Investments from strategic shareholders Maruishi Pharmaceutical and Xenoack Holdings signify understanding of the business strategy and continued support.","jir_financial_highlights":"Net Sales: Unknown (Unknown)\nOperating Loss: Unknown (Unknown)\nNet Loss Attributable to Owners of Parent: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KringlePharmaIR, #clinical_development_funding","jir_key_figures":"Costs to advance U.S. Phase III trial preparations: approx. 678 million yen\nConstruction of HGF API manufacturing capability using new manufacturing method: approx. 640 million yen\nDomestic HGF API manufacturing: approx. 310 million yen","jir_meta_title":"Kringle Pharma, Inc. \u2014 Q&A Summary Published\uff5cNovember 17, 2026","jir_meta_description":"Summary of Kringle Pharma, Inc.'s Q&A from the full-year results briefing for FY ended September 2026. Highlights include U.S. Phase III readiness, HGF API manufacturing setup, timing for vocal fold scarring treatment data disclosure, use of fundraising proceeds, and the role of strategic shareholders \u2014 key points for investment consideration.","jir_og_title":"Kringle Pharma, Inc.\uff5cQ&A Summary from Financial Results Briefing Published","jir_og_description":"Summary of key points: Ready-to-Go preparation for U.S. spinal cord injury development, HGF API manufacturing, progress on vocal fold scarring treatment, and funding objectives.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":60827,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"earnings_guidance","footnotes":""},"sector":[],"importance":[],"class_list":["post-154377","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Q&amp;A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026 - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/\",\"name\":\"Q&A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026 - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-17T08:33:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Q&#038;A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Q&A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026 - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/","url":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/","name":"Q&A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026 - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-17T08:33:03+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4884\/ir\/4884-20261117-01_wp_earnings_guidance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Q&#038;A Summary from Full-Year Financial Results Briefing for Fiscal Year Ended September 2026"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"60827","title":"KRINGLE PHARMA INC","ticker":"4884"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154377"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154377\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154377"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154377"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}